Acquisitions, Research Collaborations and Licensing Agreements - Narrative (Details) $ / shares in Units, € in Millions, shares in Millions, $ in Millions	1 Months Ended																			3 Months Ended	8 Months Ended	12 Months Ended
	Feb. 24, 2023 USD ($)	Jan. 31, 2023 USD ($)	Oct. 31, 2022 USD ($)	Sep. 30, 2022 USD ($)	Aug. 31, 2022 USD ($)	Jul. 31, 2022 USD ($)	May 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Nov. 30, 2021 USD ($)	Apr. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Jan. 31, 2021 USD ($) research_program collaboration_target	Dec. 31, 2020 USD ($)	Sep. 30, 2020 USD ($) $ / shares shares	Sep. 30, 2020 EUR (€)	Jul. 31, 2020 USD ($)	Jun. 30, 2020 USD ($)	May 31, 2020 USD ($)	Jan. 31, 2020 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Nov. 19, 2021 USD ($)	Jan. 16, 2020 USD ($)
Business Acquisition [Line Items]
Research and development																						$ 13,548.0	$ 12,245.0	$ 13,397.0
Payments to acquire productive assets																						4,388.0	4,448.0	4,429.0
Research and development expenses																						0.0	0.0	2,660.0
Inventories								$ 5,953.0												$ 5,911.0	$ 5,911.0	5,911.0	5,953.0
Contingent consideration								777.0					$ 841.0							456.0	456.0	456.0	777.0	841.0
Goodwill								21,264.0					$ 18,882.0							21,204.0	21,204.0	21,204.0	21,264.0	$ 18,882.0
IPR&D impairment charges																						1,700.0
Business combination, contingent consideration arrangements, change in amount of contingent consideration liability																						$ 146.0	(57.0)
OncoImmune
Business Acquisition [Line Items]
Equity method, ownership percentage													20.00%											20.00%
COVID-19
Business Acquisition [Line Items]
Research and development																								$ 45.0
Charges related to program discontinuation																							207.0	305.0
IPR&D impairment charges																								90.0
Business combination, contingent consideration arrangements, change in amount of contingent consideration liability																								45.0
Inventory write-off related to contract termination																								260.0
Sentinel
Business Acquisition [Line Items]
Consideration paid																$ 410.0
Inventories																9.0
Sentinel | Products and product rights
Business Acquisition [Line Items]
Finite-lived intangible assets acquired																$ 401.0
Imago BioSciences, Inc. | Subsequent Event
Business Acquisition [Line Items]
Research and development		$ 1,200.0
Payments to acquire productive assets		1,350.0
Transaction costs		60.0
Net assets acquired		200.0
Pandion Therapeutics
Business Acquisition [Line Items]
Research and development																							1,700.0
Transaction costs										$ 147.0
Consideration paid										1,900.0
Other net assets (liabilities)										$ 156.0
OncoImmune
Business Acquisition [Line Items]
Payments to acquire investment													$ 50.0
Consideration paid													423.0
Other net assets (liabilities)													(22.0)											(22.0)
Investments													33.0											33.0
Premium on shares acquired													17.0
Research and development expenses																								462.0
VelosBio
Business Acquisition [Line Items]
Research and development																							43.0	2,700.0
Consideration paid								47.0					2,800.0
Other net assets (liabilities)								$ 90.0					$ 180.0										$ 90.0	180.0
Dunboyne
Business Acquisition [Line Items]
Consideration paid														$ 302.0	€ 256
Other net assets (liabilities)														13.0
Property, plant and equipment														289.0
Research and development
Business Acquisition [Line Items]
Premium on shares acquired																								16.0
Acceleron Pharma Inc.
Business Acquisition [Line Items]
Cash paid for acquisition of business									$ 11,500.0
Transaction costs									$ 280.0
Estimated useful life of intangible assets, acquired									12 years
In-process research and development (IPR&D)																									$ 6,380.0
Other net liabilities																									(82.0)
Goodwill																									2,411.0
Cash and cash equivalents																									$ 340.0
Themis
Business Acquisition [Line Items]
Cash paid for acquisition of business																	$ 366.0
Contingent consideration																	85.0
In-process research and development (IPR&D)																	113.0
Deferred tax assets																	72.0
Other net liabilities																	32.0
Goodwill																	239.0
Cash and cash equivalents																	$ 59.0
Themis | COVID-19
Business Acquisition [Line Items]
IPR&D impairment charges																								90.0
Business combination, contingent consideration arrangements, change in amount of contingent consideration liability																								45.0
ArQule
Business Acquisition [Line Items]
Cash paid for acquisition of business																			$ 2,700.0
Transaction costs																			95.0
In-process research and development (IPR&D)																										$ 2,280.0
Other net liabilities																										(34.0)
Goodwill																										512.0
Share-based compensation payments to settle equity awards attributable to precombination service																			$ 138.0
Cash and cash equivalents																										$ 145.0
Moderna | Licensing Agreements
Business Acquisition [Line Items]
Upfront and milestone payments made to collaborative partner				$ 250.0
Orna Therapeutics | Licensing Agreements
Business Acquisition [Line Items]
Upfront and milestone payments made to collaborative partner					$ 150.0
Payments to acquire investment																				$ 100.0
Orna Therapeutics | Licensing Agreements | Development Milestones
Business Acquisition [Line Items]
Contingent payments collaborative arrangement					440.0
Orna Therapeutics | Licensing Agreements | Regulatory Milestones
Business Acquisition [Line Items]
Contingent payments collaborative arrangement					675.0
Orna Therapeutics | Licensing Agreements | Sales-Based Milestones
Business Acquisition [Line Items]
Contingent payments collaborative arrangement					$ 2,400.0
Orion Corporation | Licensing Agreements
Business Acquisition [Line Items]
Upfront and milestone payments made to collaborative partner						$ 290.0
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Subsequent Event
Business Acquisition [Line Items]
Research and development	$ 175.0
Eligible future contingent development-related payments (up to)	1,000.0
Regulatory milestones payments	2,800.0
Sales milestone payments	$ 5,500.0
Preferred stock investment in counterparty		$ 100.0
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements
Business Acquisition [Line Items]
Upfront and milestone payments made to collaborative partner						35.0	$ 30.0
Upfront and milestone payments to be made							30.0
Milestone payment to be made to collaborative partner							25.0
Research and development payments to be made to a collaborative partners							111.0
Research and development payments made to a collaborative partner																					$ 51.0
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements | Development Milestones
Business Acquisition [Line Items]
Contingent payments collaborative arrangement						82.0	90.0
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements | Regulatory Milestones
Business Acquisition [Line Items]
Contingent payments collaborative arrangement						334.0
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements | Sales-Based Milestones
Business Acquisition [Line Items]
Contingent payments collaborative arrangement						$ 485.0	780.0
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements | First Commercial Sale Milestones
Business Acquisition [Line Items]
Contingent payments collaborative arrangement							$ 290.0
Bristol Myers Squibb | Licensing Agreements
Business Acquisition [Line Items]
Royalty rate, percentage									22.00%
Royalty rate, deduction, percentage									50.00%													50.00%
Bristol Myers Squibb | Licensing Agreements | Minimum
Business Acquisition [Line Items]
Royalty rate, percentage									20.00%													20.00%
Bristol Myers Squibb | Licensing Agreements | Maximum
Business Acquisition [Line Items]
Royalty rate, percentage									24.00%													24.00%
Bristol Myers Squibb | Licensing Agreements | Regulatory Milestones
Business Acquisition [Line Items]
Contingent payments collaborative arrangement																						$ 20.0
Bristol Myers Squibb | Licensing Agreements | Sales-Based Milestones
Business Acquisition [Line Items]
Contingent payments collaborative arrangement																						$ 80.0
Gilead Sciences | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Oral and Injectable Formulations
Business Acquisition [Line Items]
Profit share by counterparty											60.00%
Profit share											40.00%
Gilead Sciences | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Oral Formulation
Business Acquisition [Line Items]
Profit share by counterparty											65.00%
Profit share											35.00%
Sales threshold											$ 2,000.0
Gilead Sciences | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Injectable Formulation
Business Acquisition [Line Items]
Profit share by counterparty											65.00%
Profit share											35.00%
Sales threshold											$ 3,500.0
Artiva Biotherapeutics, Inc. | Licensing Agreements
Business Acquisition [Line Items]
Upfront and milestone payments to be made												$ 15.0
Number of research programs | research_program												3
Number of collaboration targets | collaboration_target												3
Upfront and milestone payments												$ 30.0
Artiva Biotherapeutics, Inc. | Licensing Agreements | Minimum
Business Acquisition [Line Items]
Royalty rate, percentage												7.00%
Artiva Biotherapeutics, Inc. | Licensing Agreements | Maximum
Business Acquisition [Line Items]
Royalty rate, percentage												14.00%
Artiva Biotherapeutics, Inc. | Licensing Agreements | Development Milestones
Business Acquisition [Line Items]
Contingent payments collaborative arrangement												$ 217.5
Artiva Biotherapeutics, Inc. | Licensing Agreements | Regulatory Milestones
Business Acquisition [Line Items]
Contingent payments collaborative arrangement												570.0
Artiva Biotherapeutics, Inc. | Licensing Agreements | Sales-Based Milestones
Business Acquisition [Line Items]
Contingent payments collaborative arrangement												$ 1,050.0
Seagen
Business Acquisition [Line Items]
Research and development																								$ 616.0
Contingent payments collaborative arrangement														2,600.0
Payments to acquire investment														1,000.0
Upfront and milestone payments														$ 600.0
Forward contract indexed to issuer's equity, indexed shares (in shares) | shares														5
Share price (in dollars per share) | $ / shares														$ 200
Seagen | Tukysa
Business Acquisition [Line Items]
Upfront and milestone payments														$ 210.0
Seagen | Minimum | Tukysa
Business Acquisition [Line Items]
Royalty rate, percentage														20.00%	20.00%
Seagen | Maximum | Tukysa
Business Acquisition [Line Items]
Royalty rate, percentage														33.00%	33.00%
Seagen | Development Milestones
Business Acquisition [Line Items]
Contingent payments collaborative arrangement														$ 850.0
Seagen | Regulatory Milestones | Tukysa
Business Acquisition [Line Items]
Contingent payments collaborative arrangement														65.0
Seagen | Sales-Based Milestones
Business Acquisition [Line Items]
Contingent payments collaborative arrangement														$ 1,750.0
Sentinel | Products and product rights
Business Acquisition [Line Items]
Estimated useful life of intangible assets, acquired																15 years
IAVI
Business Acquisition [Line Items]
Upfront and milestone payments																		$ 6.5
Royalty Pharma
Business Acquisition [Line Items]
Compensation earned on arragement			$ 50.0
Additional funding by others, percentage of development costs			50.00%
Additional funding by others, development costs subject to funding			$ 375.0